Mineralys Therapeutics
- Active openings
- 3
- US-based roles
- 0
- Remote-friendly
- 0
- Last updated
- 2026-09-12
What Mineralys Therapeutics is hiring for
Open positions
3 active- Sr. Director, HCP Marketing Sep 12
- Senior Vice President, Regulatory AffairsSep 12
- Sr. Digital Product ManagerSep 10
About Mineralys Therapeutics
Claim to unlockMission, culture, and benefits - visible once this page is claimed and verified.
Updates
ENDO 2026: Lorundrostat Modulates Heart Failure Risk Biomarkers in Participants With Uncontrolled Hypertension
ESH 2026 Presentation: Lorundrostat for Hypertension in CKD: Results From the LAUNCH-HTN Trial
ASN 2025: Lorundrostat, a Novel Aldosterone Synthase Inhibitor (ASI), in Participants with Uncontrolled Hypertension, CKD, and Albuminuria: Results from Explore-CKD
AHA Hypertension 2025 Poster: Efficacy and Safety of Lorundrostat in Hypertension Patients With High Unmet Medical Need: Subgroup Analyses of the Launch-HTN Trial in Uncontrolled and Treatment-Resistant Hypertension
Lorundrostat in Participants With Uncontrolled Hypertension and Treatment-Resistant Hypertension
Phase 3 Efficacy and Safety of a Novel Aldosterone Synthase Inhibitor in Patients with Uncontrolled and Treatment-Resistant Hypertension: Launch-HTN Study